Arax Advisory Partners’s Cartesian Therapeutics RNAC Stock Holding History

Arax Advisory Partners’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$117	Buy	+19	New	+$135	﹤0.01%	3598
2025 Q4	–	Sell	-111	Closed	-$1.14K	–	4457
2025 Q3	$1.14K	Buy	+111	New	+$1.25K	﹤0.01%	3233
2024 Q4	–	Sell	-12	Closed	-$194	–	2694
2024 Q3	$194	Hold	12	–	–	﹤0.01%	2514
2024 Q2	$325	Buy	+12	New	+$286	﹤0.01%	2390

Other funds holding RNAC

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arax Advisory Partners's RNAC Position: Q1 2026 in Review

Arax Advisory Partners opened a new position in Cartesian Therapeutics (RNAC) in Q1 2026: 19 shares worth $117. The stake represents ﹤0.01% of the portfolio and ranks #3598 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in RNAC as recently as Q3 2025.

Arax Advisory Partners first reported a position in RNAC in Q2 2024 and has held it in 4 quarters since. The position peaked at $1.14K in Q3 2025. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

Arax Advisory Partners held 19 shares of Cartesian Therapeutics worth $117 as of Q1 2026.
Cartesian Therapeutics was a new Arax Advisory Partners position in Q1 2026.
Cartesian Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3598 holding.
Arax Advisory Partners first reported a position in Cartesian Therapeutics in Q2 2024 and has held it in 4 quarters since.
Arax Advisory Partners's Cartesian Therapeutics position peaked at $1.14K in Q3 2025.
83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.